The Minipig in Biomedical Research
244,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 2-4 Wochen
payback
122 °P sammeln
  • Gebundenes Buch

The first comprehensive single-source reference on the minipig, this accessible manual provides a resource for research scientists on the potential and use of the minipig as a model. Written by acknowledged experts in the field, and drawing on the authors global contacts and experience with regulatory authorities and the pharmaceutical industry, this book exposes new information to the public domain such as novel procedures and regulatory aspects. It includes basic information, experimental techniques, animal welfare issues, pharmacology, toxicology, immunology, disease models, and new horizons and perspectives.…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
The first comprehensive single-source reference on the minipig, this accessible manual provides a resource for research scientists on the potential and use of the minipig as a model. Written by acknowledged experts in the field, and drawing on the authors global contacts and experience with regulatory authorities and the pharmaceutical industry, this book exposes new information to the public domain such as novel procedures and regulatory aspects. It includes basic information, experimental techniques, animal welfare issues, pharmacology, toxicology, immunology, disease models, and new horizons and perspectives.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Anthony Dayan worked as a pathologist before joining the pharmaceutical industry as a toxicologist and subsequently returning to head a university department of toxicology in London. He has been a member of official and industrial advisory committees on animal experimentation and the safety of medicines, foods and pesticides in the UK and internationally. He has been a consultant to many companies on drug and chemical safety programmes.Kenneth Hastings was trained at the University of North Carolina at Chapel Hill and the Chemical Industry Institute of Toxicology. After Peace Corps service with the Ministry of Health, Republic of Fiji, he was a Research Associate in the Department of Anesthesiology, College of Medicine, University of Arizona. He then joined the US Food and Drug Administration, Center for Drug Evaluation and Research, Division of Anti-viral Drug Products, where he reviewed many of the early drugs for treatment of HIV/AIDS and related diseases. He served as supervisory toxicologist in the Division of Special Pathogen and Immunologic Drug Products, where he was part of review teams for tropical disease and transplant drugs. He concluded his career at FDA as an Associate Director in the Office of New Drugs. He represented the Agency on many regulatory initiatives, such as the International Conference on Harmonisation (ICH). After government service, he joined Sanofi-Aventis as Associate Vice-President for Regulatory Policy. He has served as President of the American College of Toxicology, the American Board of Toxicology, and the Immunotoxicology Specialty Section of the Society of Toxicology. Peter McAnulty was trained at the University of London, and worked on various biochemical studies at the Institute of Child Health, part of London University. He then moved to Cambridge University and the Strangeways Research Laboratory, and began biochemistry and immunology